New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:35 EDTADXSAdvaxis receives notice of allowance from USPTO for three patent applications
Advaxis announced that the USPTO has issued a notice of allowance for three U.S. patent applications with claims of each application related to the company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension. The three patent applications allowed by the USPTO cover composition of matter and methods of use for combining the Advaxis proprietary immunogenic but non-toxic recombinant tLLO fused to full and partial antigens of particular interest in the treatment of multiple cancers, including B-cell lymphoma in both humans and animals. Additional patent applications also allowed by the USPTO encompass a method of use targeting multiple critical structural and identifying elements associated with B-cells and B-cell lymphomas and allow targeting of multiple structural peptides at the same time. Also allowed separately are composition of matter and methods of use to accommodate the targeting of Advaxis treatments toward factors that are essential for tumors or metastases to form new blood vessels or that are expressed by tumor blood vessels. A method of use is allowed where multiple targets associated with angiogenesis can be targeted at the same time in animals as well as humans. These include, but are not limited to, HER2 and VEGFr2.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
09:18 EDTADXSOn The Fly: Pre-market Movers.
UP AFTER EARNINGS: Glu Mobile (GLUU), up 28.2% after reporting first quarter results and deals with Tencent and Britney Spears... Civeo (CVEO), up 3.05... TASER (TASR), up 9.6%... Virgin America (VA), up 2.7%... Noble Corp (NE), up 1.8%... Statoil (STO), up 2.8%... Alpha Natural (ANR), up 3.6%... Exxon Mobil (XOM), up 1.4%... Phillips 66 (PSX), up 1.2%... NXP Semiconductors (NXPI), up 2.4%. ALSO HIGHER: Clicksoftware (CKSW), up 27.8% after being acquired by Francisco Partners... JetBlue (JBLU), up 1.4% after being upgraded to Outperform from Neutral at Credit Suisse... WuXi PharmaTech (WX), up 16.5% after receiving going private proposal. DOWN AFTER EARNINGS: Yelp (YELP), down 17.1%... Celgene (CELG), down 2.4%... STMicroelectronics (STM), down 11.4%... Harman International (HAR), down 9%... Potash (POT), down 2.4%... Generac (GNRC), down 7%... Nokia (NOK), down 8.7%... Baidu (BIDU), down 2.6%. ALSO LOWER: Inovio Pharmaceuticals (INO), down 18.1% after 9.5M share Spot Secondary priced at $8.00... Miller Energy (MILL), down 9% after receiving 'Wells Notice'... Scorpio Tankers (STNG), down 7.5% after 15M share Spot Secondary priced at $9.30... Advaxis (ADXS), down 6% after 2.8M share Spot Secondary priced at $19.00.
09:14 EDTADXSOn The Fly: Pre-market Movers.
Subscribe for More Information
09:09 EDTADXSAdvaxis 2.8M share Spot Secondary priced at $19.00
Subscribe for More Information
06:02 EDTADXSAdvaxis 2.5M share Spot Secondary, price range $18.75-$19.25
Subscribe for More Information
April 29, 2015
19:09 EDTADXSOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTADXSAdvaxis files to sell common stock, no amount given
Subscribe for More Information
April 28, 2015
08:11 EDTADXSAdvaxis announces two USPTO patents addressing ADXS-PSA, ADXS-HER2
Advaxis announced that the United States Patent and Trademark Office has granted U.S. Patent No. 9,012,141 with composition of matter claims covering the Advaxis product candidate, ADXS-PSA, and U.S. Patent No. 9,017,660 with methods of use claims covering the Advaxis product candidate, ADXS-HER2. The first patent, which will expire on November 26, 2028, covers constructs related to ADXS-PSA, Advaxis's Lm-LLO immunotherapy candidate being developed to address prostate cancer. Specifically, the patent provides composition of matter protection for a recombinant Listeria strain encoded with recombinant fusion peptide of KLK3 peptide linked to non-KLK3 peptide. The second patent, which will expire on January 14, 2031, covers methods of use for ADXS-HER2, Advaxis's Lm-LLO immunotherapy candidate designed to target HER2 receptor expressing cancers. The patent provides method of use protection in treating HER2/Neu expressing tumors, particularly osteosarcoma, in non-human animals and companion dogs.
April 22, 2015
11:52 EDTADXSAdvaxis management to meet with Jefferies
Meeting to be held in New York on April 28 hosted by Jefferies.
April 21, 2015
13:01 EDTADXSAdvaxis presents Lm-LLO cancer immunotherapy data at AACR meeting
Advaxis announced the data of one clinical and two preclinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the American Association for Cancer Research Annual Meeting 2015, held April 18 22 in Philadelphia, Pennsylvania. On Tuesday, April 21, Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center, presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies. The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal. Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs reported at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use